SavedAdd your journal

Journals / Türk Osteoporoz Dergisi / 2014 / Cilt: 20 - Sayı: 2

Development of Osteonecrosis of the Jaw in a Patient Receiving Oral Bisphosphonates for Osteoporosis: A Case Report

Osteoporoz Tanısı ile Oral Bisfosfonat Kullanan Hastada Çene Osteonekrozu Gelişimi: Olgu Sunumu

Ekin İlke ŞEN
Nurten ESKİYURT
Sina ESMAEİLZADEH
Tuğba AYDIN
Bahar DERNEK
Pages
75–80
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the present case report, diagnosis, pathogenesis and risk factors of the BORNJ which is observed following bisphosphonate use were reviewed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Clinical importance of the bisphosphonate-related osteonecrosis of the jaw (BRONJ) which is one of the serious side effects of bisphosphonates is increasing due to the widespread use of bisphosphonates in the treatment of osteoporosis.
📊
Key Findings & Data:Since current treatment options for the BRONJ are limited, evaluation of the risk factors is very important in preventing the development of BRONJ and determining the appropriate medication in osteoporosis management.
💡
Conclusion & Impact:In the present case report, diagnosis, pathogenesis and risk factors of the BORNJ which is observed following bisphosphonate use were reviewed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Clinical importance of the bisphosphonate-related osteonecrosis of the jaw (BRONJ) which is one of the serious side effects of bisphosphonates is increasing due to the widespread use of bisphosphonates in the treatment of osteoporosis. Since current treatment options for the BRONJ are limited, evaluation of the risk factors is very important in preventing the development of BRONJ and determining the appropriate medication in osteoporosis management. In the present case report, diagnosis, pathogenesis and risk factors of the BORNJ which is observed following bisphosphonate use were reviewed.

Özet

Bisfosfonatların ciddi yan etkilerinden olan bisfosfonatlara bağlı çene osteonekrozu (BRONJ), osteoporoz tedavisinde bisfosfonatların yaygın kullanımı nedeniyle giderek artan klinik önem taşımaktadır. BRONJ tedavisinde güncel tedavi yöntemlerinin sınırlı olduğu göz önüne alındığında risk faktörlerinin değerlendirilmesi BRONJ gelişiminin önlenmesinde ve uygun medikal tedavi seçiminin belirlenmesinde önemli rol oynamaktadır. Bu olgu sunumu eşliğinde oral bisfosfonat kullanımı sonrası görülen BRONJ'un tanısı, patogenezi ve risk faktörleri gözden geçirilmiştir.

🔖

Cite This Article

ŞEN, E. İ., ESKİYURT, N., ESMAEİLZADEH, S., AYDIN, T., DERNEK, B. (2022). Development of Osteonecrosis of the Jaw in a Patient Receiving Oral Bisphosphonates for Osteoporosis: A Case Report. Türk Osteoporoz Dergisi, Cilt: 20 - Sayı: 2, 75–80. https://ajindex.com/articles/639842

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Becker DJ, Kilgore ML, Morrisey MA. The societal burden of osteoporosis. Curr Rheumatol Rep 2010;12:186-91.
  2. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7.
  3. Sharma D, Ivanovski S, Slevin M, Hamlet S, Pop TS, Brinzaniuc K, et al. Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc Cell. 2013;14:5-1. Janovská Z. Bisphosphonate-related osteonecrosis of the jaws. A severe side effect of bisphosphonate therapy. Acta Medica (Hradec Kralove). 2012;55:111-5.
  4. Kharazmi M, Persson U, Warfvinge G. Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity. J Oral Maxillofac Surg. 2012;70:2793-7. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-76.
  5. Colella G, Campisi G, Fusco V. American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg. 2009;67:2698-9.
  6. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009;67:2-12. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci. 2011;1218:38-46.
  7. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009;67:61-70.
  8. Coskun Benlidayi I, Guzel R. Oral bisphosphonate related osteonecrosis of the jaw: a challenging adverse effect. ISRN Rheumatol. 2013;2013:215034. O'Connell JE, Ikeagwani O, Kearns GJ. A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery? Ir J Med Sci. 2012;181:237-42. Papapoulos SE. Bisphosphonates: how do they w